KPI-121 1% for pain and inflammation in ocular surgery

Area of Science:

• Ophthalmology
• Drug Delivery Systems
• Pharmacology

Background:

• Post-ocular surgery pain and inflammation can impair vision and quality of life.
• Current corticosteroid formulations face challenges penetrating the ocular mucus barrier.
• Effective topical treatments are needed to manage ocular inflammation post-surgery.

Purpose of the Study:

• To evaluate the efficacy and tolerability of KPI-121 1% (INVELTYS®) for treating ocular inflammation and pain after surgery.
• To highlight the novel mucus-penetrating particle technology of KPI-121 1%.

Main Methods:

• Clinical trials were conducted to assess KPI-121 1% in patients undergoing ocular surgery.
• KPI-121 1% utilizes proprietary technology for nanoparticle-sized, mucus-penetrating particles.
• The formulation targets enhanced delivery of loteprednol etabonate to ocular tissues.

Main Results:

• KPI-121 1% demonstrated effectiveness in managing post-operative ocular inflammation and pain.
• Clinical trial results indicated that KPI-121 1% is well-tolerated by patients.
• The drug's mucopenetrative technology facilitates improved corneal penetration.

Conclusions:

• KPI-121 1% (INVELTYS®) is an effective and well-tolerated treatment for post-ocular surgery inflammation and pain.
• Its innovative mucopenetrative technology represents an advancement in ophthalmic drug delivery.
• KPI-121 1% is the sole twice-daily ocular corticosteroid approved by the FDA for this indication.